Formulation and In vitro Evaluation of Sublingual Tablets of Ranolazine

Research Article

Abstract

The aim of this study was to create and assess Sublingual tablets of Ranolazine, an effective drug for treating Angina pectoris. The method involved utilizing super disintegrants through direct compression to develop these tablets, offering advantages such as rapid onset of action and bypassing the liver. Sublingual drug delivery provides an effective and convenient approach to managing Angina. Ranolazine underwent characterization based on its physicochemical properties, including melting point, solubility, UV, and FTIR studies. Croscarmellose sodium served as the super disintegrant, while HPC, HPMC, and Starch were employed as tablet binders, and microcrystalline cellulose as tablet diluents. Ten formulations (F1-F10) underwent preparation and evaluation. The tablets exhibited hardness ranging from 4.0 to 5.8 kg/cm², friability between 0.21 and 0.46%, weight variations, disintegration time spanning from 10 to 24 seconds, and in-vitro drug release varying from 61.82 to 96.79%. Among the formulations, F1, utilizing HPC as a binder, emerged as the best formulation based on its drug release characteristics. In conclusion, this study demonstrated that the inclusion of superdisintegrants enhanced the solubility and in-vitro release of Ranolazine.